Prolific Machines reported a manufacturing productivity milestone using a light-controlled, optogenetics-driven CHO platform, posting a 21 g/L titer in a 15-day intensified fed-batch run for a monoclonal antibody. The company said the output more than doubles a cited industry standard of below 10 g/L and is aligned with a goal of reaching 25 g/L in fed-batch by the end of 2026. The update frames the platform as a route to dynamic control of gene expression, aiming to increase yields while maintaining process robustness. Management also tied the technology to the next generation of complex biologics, including multispecifics and cytokines, where conventional fed-batch approaches often underperform. For CDMO and pharma process development teams, the key takeaway is not just higher titer, but reported viability, cell density, and productivity stability indicators during the run.